MoonLake Immunotherapeutics (MLTX) Return on Capital Employed (2021 - 2026)
MoonLake Immunotherapeutics' (MLTX) quarterly Return on Capital Employed came in at 73.0% in Q1 2026, down 3671.0% year-on-year from 2.04% in Q1 2025, and down 11.48% quarter-over-quarter from 65.48% in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Return on Capital Employed (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 73.0% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 3671.0% year-over-year to 73.0% in Q1 2026; TTM through Mar 2026 was 73.0%, a 3671.0% decrease from a year earlier, with the FY2025 full-year figure at 60.35%, down 3052.0% from the prior year.
- Return on Capital Employed fell to 73.0% in Q1 2026 per MLTX's latest filing, from 65.48% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 131.73% in Q1 2022 and bottomed at 116.51% in Q3 2022.
- The 5-year median for Return on Capital Employed is 36.28% (2025), against an average of 36.65%.
- Across the five-year window, Return on Capital Employed jumped 13448 bps in 2022 and slumped 22787 bps in 2023, its largest moves.
- Year by year, Return on Capital Employed stood at 86.69% in 2022, then jumped by 88 bps to 10.75% in 2023, then sank by 180 bps to 30.09% in 2024, then tumbled by 118 bps to 65.48% in 2025, then slipped by 11 bps to 73.0% in 2026.
- Per Business Quant, the three latest MLTX Return on Capital Employed figures stand at 73.0% (Q1 2026), 65.48% (Q4 2025), and 58.94% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | MoonLake Immunotherapeutics | 1.35 Bn | 991.29 Mn | - | -73.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.00% |
| Dec 31, 2025 | -65.48% |
| Sep 30, 2025 | -58.94% |
| Jun 30, 2025 | -43.83% |
| Mar 31, 2025 | -36.28% |
| Dec 31, 2024 | -30.09% |
| Sep 30, 2024 | -21.22% |
| Jun 30, 2024 | -14.46% |
| Mar 31, 2024 | -11.37% |
| Dec 31, 2023 | -10.75% |
| Sep 30, 2023 | -11.31% |
| Jun 30, 2023 | -20.60% |
| Mar 31, 2023 | -96.14% |
| Dec 31, 2022 | -86.69% |
| Sep 30, 2022 | -116.51% |
| Jun 30, 2022 | -58.05% |
| Mar 31, 2022 | 131.73% |
| Dec 31, 2021 | -221.17% |